BRPI0415853A - sal de cloridreto de telavancina, processo para preparar um sal de cloridreto de telavancina e produto - Google Patents
sal de cloridreto de telavancina, processo para preparar um sal de cloridreto de telavancina e produtoInfo
- Publication number
- BRPI0415853A BRPI0415853A BRPI0415853-9A BRPI0415853A BRPI0415853A BR PI0415853 A BRPI0415853 A BR PI0415853A BR PI0415853 A BRPI0415853 A BR PI0415853A BR PI0415853 A BRPI0415853 A BR PI0415853A
- Authority
- BR
- Brazil
- Prior art keywords
- hydrochloride salt
- preparing
- telavancin
- telavancin hydrochloride
- product
- Prior art date
Links
- GSSIWSIRBWAZHG-ACOPVEIWSA-N telavancin hydrochloride Chemical class Cl.O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O GSSIWSIRBWAZHG-ACOPVEIWSA-N 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 4
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 150000003840 hydrochlorides Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960005240 telavancin Drugs 0.000 abstract 1
- 108010089019 telavancin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"SAL DE CLORIDRETO DE TELAVANCINA, PROCESSO PARA PREPARAR UM SAL DE CLORIDRETO DE TELAVANCINA E PRODUTO". Revelados são sais de cloridreto de telavancina tendo um teor de íon cloreto de cerca de 2,4% em peso a cerca de 4,8% em peso. Os sais revelados têm estabilidade melhorada durante armazenamento em temperatura ambientes comparados com outros sais de cloridreto. Também revelados são processos para preparar tais sais.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51335903P | 2003-10-22 | 2003-10-22 | |
| US60/513.359 | 2003-10-22 | ||
| PCT/US2004/034958 WO2005042568A2 (en) | 2003-10-22 | 2004-10-21 | Hydrochloride salts of a glycopeptide phosphonate derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0415853A true BRPI0415853A (pt) | 2007-01-02 |
| BRPI0415853B1 BRPI0415853B1 (pt) | 2017-12-12 |
| BRPI0415853B8 BRPI0415853B8 (pt) | 2021-05-25 |
Family
ID=34549267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415853A BRPI0415853B8 (pt) | 2003-10-22 | 2004-10-21 | processo para preparar um sal de cloridrato de telavancina |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7531623B2 (pt) |
| EP (2) | EP2495251B1 (pt) |
| JP (2) | JP4669478B2 (pt) |
| KR (2) | KR20120037025A (pt) |
| CN (1) | CN100417661C (pt) |
| AU (1) | AU2004285924B2 (pt) |
| BR (1) | BRPI0415853B8 (pt) |
| CA (2) | CA2726967A1 (pt) |
| DK (2) | DK1678201T3 (pt) |
| ES (2) | ES2400483T3 (pt) |
| HU (1) | HUE026769T2 (pt) |
| MX (1) | MXPA06004336A (pt) |
| PL (2) | PL2495251T3 (pt) |
| PT (2) | PT2495251E (pt) |
| SI (2) | SI1678201T1 (pt) |
| TW (1) | TWI342312B (pt) |
| WO (1) | WO2005042568A2 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI342312B (en) * | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
| EP3693017A1 (en) | 2010-12-14 | 2020-08-12 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| BR112015022716A2 (pt) * | 2013-03-13 | 2017-07-18 | Theravance Biopharma Antibiotics Ip Llc | sais de cloridrato de um composto antibiótico |
| AU2016223090A1 (en) * | 2015-02-23 | 2017-08-24 | Cumberland Pharmaceuticals Inc. | Doses and methods of administering telavancin |
| CN104877014B (zh) * | 2015-06-02 | 2018-05-11 | 宁夏泰瑞制药股份有限公司 | 一种纯化特拉万星粗品的方法 |
| CN106631902A (zh) * | 2016-09-23 | 2017-05-10 | 上海步越化工科技有限公司 | 一种特拉万星侧链癸基(2‑氧代乙基)氨基甲酸9h‑芴‑9‑甲基酯的制备方法 |
| GB2577420B (en) * | 2017-05-22 | 2022-07-06 | Insmed Inc | Glycopeptide derivative compounds and uses thereof |
| CN107629115B (zh) * | 2017-09-08 | 2021-05-07 | 福建省微生物研究所 | 一种特拉万星的纯化方法 |
| CN107629116B (zh) * | 2017-09-08 | 2021-05-07 | 福建省微生物研究所 | 一种特拉万星的纯化方法 |
| CN110824079B (zh) * | 2019-11-27 | 2021-04-13 | 苏州赛分科技有限公司 | 特拉万星的纯化方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3067099A (en) * | 1955-09-16 | 1962-12-04 | Lilly Co Eli | Vancomycin and method for its preparation |
| US4885275A (en) * | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
| EP1025852A4 (en) * | 1997-10-03 | 2001-11-07 | Fujisawa Pharmaceutical Co | VANCOMYCIN ANTIBIOTIC HYDROCHLORIDES AND METHOD FOR THE PRODUCTION THEREOF |
| EP1278549B1 (en) * | 2000-05-02 | 2008-12-10 | Theravance, Inc. | Composition containing a cyclodextrin and a glycopeptide antibiotic |
| UA75083C2 (uk) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| TWI233932B (en) * | 2001-08-24 | 2005-06-11 | Theravance Inc | Process for purifying glycopeptide phosphonate derivatives |
| TWI312785B (en) * | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
| TWI275594B (en) * | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
| TWI342312B (en) | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
-
2004
- 2004-10-18 TW TW093131554A patent/TWI342312B/zh not_active IP Right Cessation
- 2004-10-21 AU AU2004285924A patent/AU2004285924B2/en not_active Ceased
- 2004-10-21 MX MXPA06004336A patent/MXPA06004336A/es active IP Right Grant
- 2004-10-21 SI SI200431990T patent/SI1678201T1/sl unknown
- 2004-10-21 CA CA2726967A patent/CA2726967A1/en not_active Abandoned
- 2004-10-21 DK DK04796022.4T patent/DK1678201T3/da active
- 2004-10-21 KR KR1020127004624A patent/KR20120037025A/ko not_active Ceased
- 2004-10-21 HU HUE12169694A patent/HUE026769T2/hu unknown
- 2004-10-21 PT PT121696942T patent/PT2495251E/pt unknown
- 2004-10-21 KR KR1020067007648A patent/KR101166250B1/ko not_active Expired - Fee Related
- 2004-10-21 BR BRPI0415853A patent/BRPI0415853B8/pt not_active IP Right Cessation
- 2004-10-21 CN CNB2004800312205A patent/CN100417661C/zh not_active Expired - Lifetime
- 2004-10-21 PL PL12169694T patent/PL2495251T3/pl unknown
- 2004-10-21 EP EP12169694.2A patent/EP2495251B1/en not_active Expired - Lifetime
- 2004-10-21 EP EP04796022A patent/EP1678201B1/en not_active Expired - Lifetime
- 2004-10-21 PT PT47960224T patent/PT1678201E/pt unknown
- 2004-10-21 ES ES04796022T patent/ES2400483T3/es not_active Expired - Lifetime
- 2004-10-21 SI SI200432167T patent/SI2495251T1/sl unknown
- 2004-10-21 US US10/970,128 patent/US7531623B2/en active Active
- 2004-10-21 ES ES12169694.2T patent/ES2477268T3/es not_active Expired - Lifetime
- 2004-10-21 CA CA2543009A patent/CA2543009C/en not_active Expired - Lifetime
- 2004-10-21 WO PCT/US2004/034958 patent/WO2005042568A2/en not_active Ceased
- 2004-10-21 DK DK12169694.2T patent/DK2495251T3/da active
- 2004-10-21 JP JP2006536805A patent/JP4669478B2/ja not_active Expired - Fee Related
- 2004-10-21 PL PL04796022T patent/PL1678201T3/pl unknown
-
2008
- 2008-04-08 US US12/082,096 patent/US8003755B2/en active Active
-
2010
- 2010-08-24 JP JP2010187705A patent/JP2011016820A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211313A (pt) | Misturas de biocidas contendo halogênio, estabilizantes de halogênio e biocidas contendo nitrogênio | |
| BR9407047A (pt) | Processo para separaçao de uma proteina de uma soluçao aquosa de proteinas | |
| BRPI0416143A (pt) | sais farmaceuticamente aceitáveis de compostos de quinolinona tendo propriedades farmacêuticas aperfeiçoadas | |
| EA200100412A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
| BRPI0012688B8 (pt) | método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas | |
| BR0211122A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
| BRPI0517916B8 (pt) | comprimido compreendendo carbonato de sevelamer e cloreto de sódio, e, uso de um comprimido | |
| ATE252572T1 (de) | 5-ht1f agonisten | |
| BR0113494A (pt) | Processo para a preparação de uma formulação sólida herbicida, e, uso de uma formulação sólida herbicida | |
| TR200400238T4 (tr) | ''Perindopril tert-bütilamin tuzunun alfa kristalin şekli'' | |
| NO992463L (no) | N-(aryl/heteroarylacetyl)aminosyreestere, farmas°ytiske sammensetninger som innbefatter det samme, og fremgangsmÕter for inhibering av <beta>-amyloidpeptidfrigivelse og/eller dens syntese ved anvendelse av slike forbindelser | |
| BRPI0415853B8 (pt) | processo para preparar um sal de cloridrato de telavancina | |
| DE602004014791D1 (de) | Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen | |
| BR0309933A (pt) | (s)-4-amino-5-cloro-2-metoxi-n-[1-[1-(2-tetraidrofurilc arbonil)-4-piperidinil-metil]-4-piperidinil] benzamida, processo para sua preparação, composição farmacêutica contendo o mesmo e intermediários obtidos desta forma | |
| BR0307782A (pt) | Compostos azabiciclo para o tratamento de doença | |
| ATE282610T1 (de) | Heterozyklische verbindungen mit faktor xa hemmender wirkung | |
| BR9908702A (pt) | Composto, processos para inibir sìntese de óxido nìtrico em um paciente, para inibir seletivamente sìntese de óxido nìtrico produzido pela no sintase indutìvel no óxido nìtrico produzido pelas formas constitutivas de no sintase em um paciente e para diminuir nìveis de óxido nìtrico em um paciente, e, composição farmacêutica | |
| DE69534120D1 (de) | Topisch anzuwendende ketoconazol enthaltende emulsionen | |
| BR0008112A (pt) | Agonistas de 5-ht 1f | |
| KR910004599A (ko) | 1,3-디하이드로-1-(피리디닐아미노)-2h-인돌-2-온, 이들의 제조방법 및 이들의 약제로서의 용도 | |
| EA200500701A1 (ru) | Новая кристаллическая форма натриевой соли 3-пиридил-1-гидроксиэтилиден-1,1-бисфосфоновой кислоты | |
| PT854724E (pt) | Metodo de tratar a doenca navicular em cavalos | |
| HUT77560A (hu) | Trombin inhibitort tartalmazó, tárolás közben stabil, vizes, infúziós törzsoldat és eljárás előállítására | |
| BR0311365A (pt) | Sal de adição de ácido farmaceuticamente aceitável, processo para a preparação de um sal de adição de ácido formulação farmacêutica, uso de um sal de adição de ácido, e, método de tratamento de uma condição onde a inibição da trombina é requerida | |
| IT1301993B1 (it) | Processo per la preparazione di zofenopril sale di calcio. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/12/2017, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25A | Requested transfer of rights approved | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2693 DE 16-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |